A Dose Escalation Study of NK-92 Cell Infusions in Patients With Hematological Malignancies in Relapse After Autologous Stem Cell Transplantation.
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs CST 101 (Primary)
- Indications Haematological malignancies; Hodgkin's disease; Leukaemia; Lymphoma; Myeloma
- Focus Adverse reactions
- 31 Jul 2017 Results from this trial have been published in the journal Oncotarget, according to NantKwest media release.
- 31 Jul 2017 Final results published in NantKwest media release.
- 21 Jun 2016 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History